Francer is Lilly’s vice president, head of global regulatory policy and strategy. Cruz is Lilly’s senior vice president, ...

The Danish company Genmab plans to buy Merus, the maker of a promising head and neck cancer drug, in a deal worth roughly $8 ...

Insurance companies continue to innovate. On Oct. 1, Cigna will roll out a policy that tracks how physicians bill. It will ...

Perimenopause brings real symptoms and a booming market of supplements, apps, and therapies. What’s hype, what’s helpful, and ...

The more we talk, debate, even sometimes argue, the more we can live well with a mind altered by these progressive, disabling ...

MoonLake Immunotherapeutics tried hard to spin the poor results of its candidate for an autoimmune skin condition.

Harvard's T.H. Chan School of Public Health faces a harsh new reality: the government is shifting away from funding public ...

GSK CEO Emma Walmsley is stepping down next year after leading the company since 2017, aiming to pivot the U.K. firm into an innovative pharma company.

Mifepristone has played a disruptive and transformational role in today’s abortion access landscape, writes Plan C’s Elisa ...

Our concern is the harm imposed on people with mental health conditions, no matter which terms are used. Identity is solely ...

Drugmakers are scrambling to make last-minute announcements ahead of a Trump deadline on Monday for the firms to lower U.S.

Whistleblowers are suing UnitedHealth Group over its use of a peripheral artery disease test, called QuantaFlo, to increase ...